Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds

A New Study Is Changing How We Think About Obesity Treatment

Imagine trying every diet, every pill, every structured program for years, and still watching the scale barely move. That's the reality for millions of people living with obesity. And now, a new study is giving both patients and clinicians something concrete to think about, specifically whether a minimally invasive procedure might outperform one of the most talked-about weight loss medications available today.

The study, presented at ESGE Days 2026, took a good hard look at endoscopic sleeve gastroplasty (ESG) versus oral semaglutide for short-term weight loss in folks dealing with obesity. The results? Clear as day. ESG led to way more weight loss over the short term.

What Is Endoscopic Sleeve Gastroplasty?

ESG is what you'd call a minimally invasive procedure. A doctor, armed with an endoscope, goes through the mouth to stitch up the inside of your stomach. This means your stomach shrinks by a hefty 70 to 80 percent. And guess what? No cuts on the outside.

It's not the same as traditional bariatric surgery. There's no cutting, no stapling, and recovery is typically faster. Straight up, it sits somewhere between lifestyle intervention and surgical intervention on the treatment spectrum.

Most people are discharged the same day or after one night in hospital. That alone makes it appealing compared to more invasive options.

How Does Oral Semaglutide Compare?

Oral semaglutide, branded as Rybelsus, is a GLP-1 receptor agonist. Think of it as a mimic artist for a gut hormone that keeps your appetite and blood sugar in check. It's the pill version of the drug class that’s been making waves in obesity treatments with its injectable form.

To be fair, oral semaglutide has shown real, meaningful results in clinical trials. Research published on PubMed has shown oral semaglutide produces clinically significant weight reduction in people with type 2 diabetes and obesity. But here’s the catch: the oral version isn’t absorbed as well as the injectable one, and that’s a big deal.

So when you're comparing it directly to a structural intervention like ESG, the gap in short-term outcomes starts to make sense.

What the Study Actually Found

The comparative study, showcased at ESGE Days 2026, roped in adults with obesity and tracked how much weight they shed in the short term. Folks who opted for ESG lost a lot more weight than those who were on oral semaglutide.

Patients treated with endoscopic sleeve gastroplasty experienced significantly greater short-term weight loss than those on oral semaglutide, suggesting that structural stomach modification may offer a faster initial response for people with obesity.

That's not a small distinction. Short-term outcomes matter enormously for patient motivation and metabolic health. Early weight loss often predicts better long-term adherence and outcomes.

Honestly, this kind of head-to-head comparison has been overdue. The obesity treatment field has expanded rapidly, but rigorous comparative data across modalities has been harder to come by.

Who Might Be a Candidate for ESG?

Not everyone makes the cut for ESG. It's usually for adults with a body mass index of 30 or more. And let's be honest, if you've tried everything else and still aren't seeing results, this might be an option. It's also for those who just can't or don't want to deal with traditional bariatric surgery.

Here's the thing, though. ESG isn't widely available everywhere, and cost can be a significant barrier. Insurance coverage varies considerably, and many patients end up paying out of pocket.

But there are reasons some folks can't go this route. If you've got certain gastrointestinal issues, big hiatal hernias, or have had stomach surgery before, you might not qualify. You're gonna need a sit-down with a gastroenterologist or a bariatric specialist to really figure things out.

The Limitations Worth Knowing

This study? It zoomed in on short-term outcomes. That's a biggie to keep in mind. Dropping pounds in three or six months doesn't always mean the weight stays gone for two or five years.

Long-term? That's the tricky bit where many treatments, even surgeries, get complicated. And oral semaglutide might just bridge that gap if used regularly over time. But hey, this study didn’t get to that part yet.

Mayo Clinic says endoscopic sleeve gastroplasty has a low complication rate. But let's be real, any procedure has its risks. Nausea, pain, and in rare cases, leaks or bleeding could happen.

I'll be honest. It's frustrating that obesity research still leans so heavily on short-term data. Patients deserve longer follow-up periods before making life-altering treatment decisions.

What This Means for Obesity Treatment Going Forward

The obesity treatment scene's a tangled web these days. Sure, GLP-1 meds have really shaken things up. But don't kid yourself, this study says some folks might still need a procedure. Depends on your situation and timing.

Some docs are thinking about mixing things up. They're pairing ESG with meds to see if they can get better results. It's a new idea on the block, but we don't have all the answers yet.

If you're exploring weight loss options and want to understand how supplements and lifestyle approaches fit into the picture, reading an honest FitSpresso review for real-world weight loss results might give you useful context on where non-prescription products sit in the broader landscape.

And for those curious about other evidence-based approaches to fat reduction, a detailed look at whether Flash Burn really works covers the science behind thermogenic-style support tools in plain language.

Frequently Asked Questions

What is endoscopic sleeve gastroplasty and how does it work?

Endoscopic sleeve gastroplasty, or ESG, is a slick way to lose weight without major surgery. They shrink your stomach using an endoscope instead of a scalpel. No outside cuts and you're probably back on your feet faster. It basically limits how much chow your stomach can handle, so you end up eating less.

Is oral semaglutide effective for weight loss?

Oral semaglutide does help with weight loss, but not as much as its injectable cousin. Studies show it can really cut pounds, especially if you're dealing with obesity or type 2 diabetes. But here's the kicker: results vary and you've got to be diligent with when you pop those pills.

How does ESG compare to traditional weight loss surgery?

ESG's a bit friendlier than the big guns like gastric sleeve surgery. No chopping out stomach parts, and there's usually less risk. But don't get it twisted—surgery might pack a bigger punch for those with serious obesity issues. It's all about what's best for you and your health.

Can you combine ESG with weight loss medications?

Some specialists are looking into mixing ESG and GLP-1 meds to see if it boosts results. But honestly, the solid clinical trial data? Still pretty thin. Early signs look good, sure. But before jumping on this, have a real chat with a healthcare pro who knows their stuff.

How do I know which weight loss treatment is right for me?

Your treatment really hinges on a few things. Your BMI, overall health, past weight loss attempts, and what you actually prefer. Best bet? Have a sit-down with a bariatric specialist or an obesity doc. They're the ones who can really weigh your options. No one-size-fits-all here. Usually, tailoring it to you gets the best results.

This article is for informational purposes only and